Now Available: Final Rule for FDAAA 801 and NIH Policy on Clinical Trial Reporting

Safety and Efficacy of Atiprimod Treatment for Patients With Low to Intermediate Grade Neuroendocrine Carcinoma

This study has been completed.
Information provided by:
Callisto Pharmaceuticals Identifier:
First received: October 11, 2006
Last updated: December 17, 2007
Last verified: December 2007
No Study Results Posted on for this Study
  Study Status: This study has been completed.
  Study Completion Date: September 2007
  Estimated Primary Completion Date: No date given